DSS's Role in Evaluating the Diagnosis and Treatment System of Ischemic Cardiovascular and Cerebrovascular Diseases

Acute Myocardial Infarction Clinical Trial

Official title:

The Research on DSS in Evaluating the Diagnosis and Treatment System of Acute Ischemic Cardiovascular and Cerebrovascular Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04359589
• Other study ID #: 2019ZDLSF01-01-01
• Status: Recruiting
• Start date: July 22, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2021
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: Xiaopu Zheng, MD
• Phone: 0086-029-85323818
• Email: gaokenkx[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: Acute ischemic cardiovascular and cerebrovascular diseases are a kind of diseases with high incidence, rapid progression, poor prognosis and high mortality and disability rate of the circulatory system, mainly including acute myocardial infarction, acute ischemic stroke and acute limb ischemia, which place a heavy burden on individuals, families and society due to their severe prognosis and high medical costs. At present, the diagnosis and treatment of ischemic cardiovascular and cerebrovascular diseases mainly focus on single organ diagnosis and treatment of target organs, lacking of indicators to comprehensively evaluate the body's pathophysiology. As ischemic disease of the circulatory system, ischemic cardiovascular and cerebrovascular diseases have common pathophysiological basis such as ischemia, hypoxia and inflammation. These common pathophysiological basis suggests that different acute ischemic cardiovascular and cerebrovascular diseases can be monitored and evaluated from an integrated perspective, it suggests the possibility of comprehensive diagnosis, evaluation and treatment guidance. At present, the "circulatory integration" therapy represented by the combined treatment of heart and brain has achieved certain results, but there is no corresponding evaluation system to provide accurate guidance. Therefore, with the concept of "circulation integration", it is an urgent problem to find the common indicators of the circulation system and construct the hierarchical diagnosis and subsequent evaluation system of acute cardiovascular and cerebrovascular integration. The development of efficient and comprehensive stratified diagnosis and prognosis evaluation system is of great significance in clinical, market and social aspects.

At the early stage of the efforts our team, it was found that Dan Shen Su-(±)-3, 4-dihydroxyphenylacetic acid (DSS) could be detected in the plasma and urine of patients with acute myocardial infarction and ischemic stroke through metabolomics. It has been proved that it can be generated by the transformation of dihydroxyphenylalanine by proteus mirabilis, and its structure is consistent with the water-soluble component of salvia miltiorrhiza, which is related to the body's states of ischemia, hypoxia and inflammation. The findings provide a material basis for the "circulatory integration" assessment of acute ischemic cardiovascular and cerebrovascular diseases.

Objectives: This study aims at acute ischemic cardiovascular and cerebrovascular diseases, with the concept of "circulatory integration", to build a hierarchical diagnosis and prognosis evaluation system with DSS as the core, in order to improve the diagnosis rate and cure rate, improve the prognosis and reduce mortality of ischemic cardiovascular diseases.

Methods: The project included 500 patients with acute myocardial infarction, 300 patients with acute ischemic stroke, 300 patients with acute lower limb ischemia, and 200 healthy controls in the Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, Peoples R China. Plasma and urine were collected during the disease process. Various relevant clinical indicators including DSS level were included, COX model was applied to analyze the influence of multiple factors on the prognosis of the above diseases, and the indicators were screened and the integrated stratified diagnosis and prognosis evaluation system of acute ischemic cardio-cerebrovascular system with DSS as the core were established. The newly established integrated stratified diagnosis and prognosis assessment system was used to evaluate 200 patients with each of the three diseases, and the sensitivity and specificity of the new assessment system were tested. And a simple, rapid and accurate method for detecting DSS was developed.

Description:

The experiments as follows:

Experiment 1. Observe the dynamic changes of DSS level in acute ischemic cardiovascular and cerebrovascular diseases of different severity.

1. Research object Acute myocardial infarction (AMI) group: 500 patients with AMI; Acute ischemic stroke group: 300 patients with acute ischemic stroke; Acute lower limb ischemia group: 300 subjects with acute lower limb ischemia; Control group: 200 healthy volunteers were included as controls. All the subjects were from the first and second affiliated hospitals of the Xi'an Jiaotong University and the Shaanxi Provincial People's Hospital;

2. Collecting indicators Peripheral blood and morning urine were collected from the patients and the volunteers after admission on the first, second, third and seventh days for DSS detection. The investigators collected several demographics, clinical and analytical parameters. Age, gender, height and weight were recorded, and body mass index (kg/m2) was calculated. Blood pressure (BP) was measured three times or more by a nurse while patients were seated after 5 min of rest. Several parameters, including myocardial enzyme, serum uric acid, total cholesterol, total triglycerides low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, estimated glomerular filtration rate and high sensitivity C-reactive protein were measured. The patient was included in all the clinical data after admission and as the admission diagnosis, including: medical history (including risk factors), physical examination, laboratory examination, imaging examination, nursing report, records of interventional operation and all the indicators of in-hospital examination.

3. Analyze the regularity curve of DSS level in disease DSS levels of blood and urine were detected by gas chromatography -mass spectrometry (GC-MS). In the disease progression of patients with AMI, acute ischemic stroke and acute lower limb ischemia, the difference of DSS production was analyzed, and the regular curve of the dynamic change process of ischemic cardiovascular and cerebrovascular diseases was plotted based on the normal control group.

Experiment 2. To establish an assessment system of "circulatory integration" for acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core.

1. The Clinical outcomes on follow up Adverse events (survival outcome) were observed and recorded in the hospital and at 1, 3, 6, and 12 months after discharge. Major adverse events mainly include disease recurrence, cardiac death and all-cause death. The time of recurrence, complication or death, type of complication and cause of death were recorded in detail.

2. Establish a diagnosis and treatment evaluation system Blood and urine DSS levels were measured by GC-MS. COX regression model analysis, including DSS level, basic information, risk factors, symptoms, physical examination, laboratory tests, image examination and electrocardiogram, assess the influence of various factors on major adverse events in patients with acute ischemic cardiovascular and cerebrovascular diseases and the prognosis of three diseases. Moreover, these indicators were used to build a scoring system, and analyze its correlation with prognosis.

Experiment 3. To verify the "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core

1. Research Object AMI group: 200 patients with AMI; Acute ischemic stroke group: 200 patients with acute ischemic stroke; Acute lower limb ischemia group: 200 subjects with acute lower limb ischemia; All these subjects were from the first and second affiliated hospitals of the Xi'an Jiaotong University and the Shaanxi Provincial People's Hospital;

2. Collecting Indicators Peripheral blood and morning urine were collected and measured.

3. Follow up and record the outcome The major adverse events were observed and recorded in the same way as in the above-mentioned experiment.

4. Verify the diagnosis and treatment evaluation system The newly established "circulatory integration" diagnosis and treatment evaluation system of acute ischemic cardiovascular and cerebrovascular diseases with DSS as the core was used to predict the prognosis of the newly included 600 patients with acute ischemic cardiovascular and cerebrovascular diseases. This paper analyzes the specificity and sensitivity of the newly built "circular integration" diagnosis and treatment evaluation system through its disease evaluation and actual adverse events.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1900
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• AMI patients:

• Patients with age between 18 to 75.

• Patients with acute ST-segment elevation myocardial infarction less than 12 hours.

• Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

• Acute ischemic stroke patients:

• Patients with age between 18 to 75.

• Patients with acute ischemic stroke less than 12 hours.

• National institutes of health stroke scale (NIHSS) scores ranged from 4 to 20.

• Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

• Acute lower limb ischemia patients:

• Patients with age between 18 to 75.

• Patients with typical " 6P " symptom within 14 days: pain, pulselessness, pallor, paresthesia, paralysis and poikilothermia.

• The magnetic resonance imaging and ultrasonography of the lower extremity artery showed that there was ischemia in the lower extremity.

• Without taking DSS and dihydroxyphenylalanine-containing drugs at least one week before admission.

Exclusion Criteria:

• • Patients with history of cardiogenic shock or cardiopulmonary resuscitation.

• Woman during pregnancy or lactation or anyone with mental disorder.

• A self-identified history of stroke, renal failure, severe arrhythmia or malignant tumor.

• Previous coronary artery bypass graft surgery.

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Acute Myocardial Infarction
• Cardiovascular Diseases
• Cerebrovascular Disorders
• Infarction
• Ischemia
• Ischemic Cardiovascular Disease
• Myocardial Infarction

Locations

Country	Name	City	State
China	First Affiliated Hospital Xi'an Jiaotong University	Xi'an	Shaanxi
China	Shaanxi Provincial People's Hospital	Xi'an	Shaanxi

Sponsors (3)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University	Second Affiliated Hospital of Xi'an Jiaotong University, Shaanxi Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of disease recurrence	Incidence of disease recurrence,including acute myocardial infarction, ischemic stroke and acute lower limb ischemia.	12 months after admission
Primary	Incidence of cardiac death	All deaths were considered to have been from cardiac causes unless a explicit noncardiac cause could be documented.	12 months after admission
Primary	Incidence of all-cause death	All deaths were taken into account unless there is a definite cause of accidental death.	12 months after admission